Last reviewed 2026-04-22 · How we verify

Adalimumab originator

Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.

Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Psoriasis, Crohn's disease.

At a glance

Mechanism of action

Adalimumab blocks TNF-α, a key pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. By preventing TNF-α from binding to its receptors on immune cells, it suppresses the inflammatory cascade and reduces disease activity in conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease.

Approved indications

• Rheumatoid arthritis
• Psoriasis
• Crohn's disease
• Ulcerative colitis
• Ankylosing spondylitis
• Psoriatic arthritis

Common side effects

• Injection site reactions
• Upper respiratory tract infections
• Headache
• Serious infections
• Tuberculosis reactivation

Key clinical trials

• Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
• Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis (PHASE4)
• Yuflyma® (Adalimumab), Patient Experience After Switching
• Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab) (PHASE1)
• Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
• Evaluation of the Safety and Effectiveness of Switching From Humira® to Imraldi® in Flanders (PHASE4)
• A 12-month Real Life Study of IBD Patients Switched From Adalimumab Originator Humira® to One of Its Biosimilar
• Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.